Professor Sir Munir Pirmohamed MB ChB (Hons), MRCP, PhD, FRCP, FRCP(E), FBPharmacolS

Research Group Membership

• Pharmacogenetics
• Epilepsy Research

Research Grants

Clinical Lecturer position in Clinical Pharmacology & Therapeutics

LABCORP DRUG DEVELOPMENT (UK)

September 2020 - August 2024

An Adaptive-design Randomised Trial of Baclofen in the Treatment of Alcohol Use Disorder in Patients with Liver Cirrhosis

DEPARTMENT OF HEALTH & SOCIAL CARE (UK)

October 2021 - March 2027

Medicines Data Resource

HEALTH DATA RESEARCH UK - HDRUK (UK)

April 2022 - March 2023

Genomic Medicine Service Alliance (GMSA)

MANCHESTER UNIVERSITY NHS FOUNDATION TRUST (UK)

March 2020 - August 2024

Two-way risk communication mobile application versus traditional methods of adverse drug reaction reporting in Uganda: a randomized controlled trial

MEDICAL RESEARCH COUNCIL

January 2022 - January 2025

Provision of a MassArray Mass-spectrometry based multiplex genotyping platform (Agena Biosciences).

MEDICAL RESEARCH COUNCIL

July 2023 - June 2025

The organisation and diffusion of translational research: Can cardiovascular medicine learn from oncology? Case studies of pharmacogenomics in the NHS

ECONOMIC AND SOCIAL RESEARCH COUNCIL

September 2022 - August 2025

Understanding adverse drug reactions of dolutegravir and isoniazid in HIV-positive Ugandans: incidence, risk factors, management and patient-reporting

MEDICAL RESEARCH COUNCIL

January 2023 - December 2027

Personalising renal function monitoring and interventions in people living with heart failure: RENAL-HF (RENAL-HF)

DEPARTMENT OF HEALTH & SOCIAL CARE (UK)

February 2022 - January 2027

Improving the utility of dihydropyrimidine dehydrogenase genetic testing in the NHS

NHS RACE AND HEALTH OBSERVATORY (UK)

April 2022 - October 2024

A personalised approach to manage adverse reactions to CFTR modulator therapy in patients with cystic fibrosis

MEDICAL RESEARCH COUNCIL

November 2022 - October 2025

Centre for Drug Safety (CDSS) (funding for salaries)

LIVERPOOL UNIVERSITY HOSPITALS NHS FOUNDATION TRUST (UK)

May 2020 - March 2022

Assessing druGs for COVID19 In early cLinical phase Expeditiously (AGILE)

MEDICAL RESEARCH COUNCIL

May 2020 - June 2025

Pharmacogenetics of Steroid-Induced Glaucoma

FIGHT FOR SIGHT (UK)

January 2020 - April 2025

Better Care Northern Partnership

HEALTH DATA RESEARCH UK - HDRUK (UK)

May 2020 - March 2028

NIHR ARC 2 national social care implementation projects

DEPARTMENT OF HEALTH & SOCIAL CARE (UK), LCCG - LIVERPOOL CLINICAL COMMISSIONING GROUP (UK)

October 2019 - March 2026

Accelerating Research & Development for Advanced Therapies (ARDAT)

BAYER AG (GERMANY), EUROPEAN COMMISSION

November 2020 - October 2025

Postdoctoral Fellowship - Dr Richard Turner

HEALTH EDUCATION ENGLAND (UK)

February 2018 - July 2023

Pharmacogenetics & Stratified Medicine Network

PRECISION MEDICINE CATAPULT LIMITED (UK)

October 2016 - September 2017

Warfarin Global Health Research Group (WarPATH)

DEPARTMENT OF HEALTH & SOCIAL CARE (UK)

June 2017 - August 2022

Support for the Pharmacology Research Portfolio

ROYAL LIVERPOOL AND BROADGREEN UNIVERSITY HOSPITALS NHS TRUST (UK)

April 2019 - March 2020

A new generation of Crystallographic detector for Multi-user Barkla X-ray laboratory

BIOTECHNOLOGY & BIOLOGICAL SCIENCE RESEARCH COUNCIL

July 2017 - July 2018

A multimodal imaging platform with real-time super-resolution for research across the life sciences

BIOTECHNOLOGY & BIOLOGICAL SCIENCE RESEARCH COUNCIL

May 2018 - April 2019

Alcohol dependence and associated disease: determinants, pathogenesis and treatment (Andrew Thompson)

MEDICAL RESEARCH COUNCIL

February 2018 - September 2021

Immune-checkpoint therapy in non-small cell lung carcinoma: molecular characterisation of tumour microenvironment to improve anti-PD1/PD-L1 drug class.

MEDICAL RESEARCH COUNCIL

August 2017 - February 2021

MRC Innovation Fellowship (Boyd)

MEDICAL RESEARCH COUNCIL

August 2017 - May 2021

The role of transporters in the uptake of AV-101

VISTAGEN THERAPEUTICS, INC (USA)

September 2017 - February 2023

UK pharmacogentics and stratified medicine network

NORTHERN HEALTH SCIENCE ALLIANCE LIMITED (UK)

October 2016 - September 2018

Support for the Pharmacogenetics and Stratified Medicine Network

NHS ENGLAND (UK)

October 2017 - October 2018

Magic Study

ALDER HEY CHILDREN'S CHARITY (UK)

March 2017 - February 2018

Bench Fees - Wedad Alhassan K Mawkili - 201309650

ROYAL EMBASSY OF SAUDI ARABIA CULTURAL BUREAU IN LONDON (UK)

February 2018 - September 2021

Support for the Pharmacogenetics and Stratified Medicine Network

DEPARTMENT OF HEALTH & SOCIAL CARE (UK)

November 2017 - July 2019

PGX Network Sponsorship

UCB BIOPHARMA SPRL (BELGIUM), UCB PHARMA LTD (UK)

October 2016 - September 2018

Can the SAVSNET informatics systems be used to improve signal identification and reporting of adverse drug reactions?

DEPARTMENT FOR ENVIRONMENT, FOOD AND RURAL AFFAIRS (UK)

February 2019 - October 2022

UK pharmacogenetics and stratified medicine network

ACADEMIC HEALTH SCIENCE NETWORK NW COAST (NWCAHSN) (UK)

October 2016 - September 2017

Exploring the interaction of gut microbiome, genetic and immunological factors in gastrointestinal toxicity of immune checkpoint inhibitors.

MEDICAL RESEARCH COUNCIL

February 2018 - March 2021

Support for the Pharmacogenetics and Stratified Medicine Network

BRISTOL-MYERS SQUIBB PHARMACEUTICALS LTD (UK)

March 2018 - August 2018

Personalised Medicine Approaches for Space Exploration

EUROPEAN SPACE AGENCY (FRANCE)

April 2018 - September 2022

Development of screening approaches to assess to intrinsic immunogenicity of drugs and novel chemicals

BIOTECHNOLOGY & BIOLOGICAL SCIENCE RESEARCH COUNCIL

March 2018 - May 2021

Systems pharmacology approaches to drug-induced hypersensitivity reactions

MALAYSIAN GOVERNMENT (MALAYSIA)

March 2015 - February 2018

Developing personalised renal function monitoring (CLAHRC)

LIVERPOOL HEART AND CHEST NHS FOUNDATION TRUST (UK)

April 2015 - December 2018

Drug induced liver injury due to tuberculosis treatment: predictive biomarkers and genetic associations

DEPARTMENT FOR BUSINESS, INNOVATION AND SKILLS (UK)

March 2015 - September 2019

Ubiquitous Pharmacogenomics (U-PGx): Making actionable pharmacogenomic data and effective treatment optimization accessible to every European citizen.

EUROPEAN COMMISSION

January 2016 - December 2021

Bench Fees for Gospel Nwikue.

RIVERS STATE SUSTAINABLE DEVELOPMENT AGENCY (NIGERIA)

February 2015 - January 2018

Liverpool Health Genomics Laboratory

LIVERPOOL HEALTH PARTNERS (UK)

March 2015 - February 2018

North West England MRC Fellowship Scheme in Clinical Pharmacology and Therapeutics

ELI LILLY AND COMPANY LTD (UK), MEDICAL RESEARCH COUNCIL, NOVARTIS PHARMACEUTICALS UK LTD (UK), ROCHE PRODUCTS LTD (UK), UCB PHARMA LTD (UK)

May 2016 - June 2025

2014 allocation - Wellcome ISSF non clinical fellowships

WELLCOME TRUST (UK)

May 2015 - October 2018

Identification of efficacy predictors for clopidogrel using integrated systems pharmacology approach

DEPARTMENT FOR BUSINESS, INNOVATION AND SKILLS (UK)

February 2016 - July 2018

A prospective investigation of β-lactam allergy in patients with cystic fibrosis to define drug immunogenicity

CYSTIC FIBROSIS TRUST (UK)

December 2011 - August 2016

A pragmatic randomised controlled trial comparing the effectiveness and cost effectiveness of levetiracetam and zonisamide versus standard treatments for epilepsy: a comparison of Standard And New Antiepileptic Drugs (SANAD-II)

DEPARTMENT OF HEALTH & SOCIAL CARE (UK)

June 2012 - November 2019

The response of the liver to chemical stress, a molecular and proteomic investigation of paracetamol-induced hepatotoxicity.

WELLCOME TRUST (UK)

September 2001 - September 2005

Genetic predisposition to clozapine agranulocytosis

MERSEY CARE NHS FOUNDATION TRUST (UK)

March 2011 - March 2019

North West Coast CLAHRC

DEPARTMENT OF HEALTH & SOCIAL CARE (UK), LCCG - LIVERPOOL CLINICAL COMMISSIONING GROUP (UK), MERSEY CARE NHS FOUNDATION TRUST (UK)

January 2014 - June 2021

PhD Studentship.

ROYAL LIVERPOOL AND BROADGREEN UNIVERSITY HOSPITALS NHS TRUST (UK)

October 2004 - September 2007

NHS informatics support to improve research recruitment

THE CHESHIRE AND MERSEYSIDE COMPREHENSIVE LOCAL RESEARCH NETWORK (UK)

January 2013 - March 2014

The role of multidrug transporters in causing pharmacoresistance in epilepsy

MEDICAL RESEARCH COUNCIL

January 2010 - January 2013

Chemical, clinical and molecular aspects of adverse drug reactions in man.

WELLCOME TRUST (UK)

January 1999 - August 2001

Psoriasis stratification to optimise relevant therapy (PSORT)

MEDICAL RESEARCH COUNCIL

September 2014 - May 2021

The Interactions Between Clostridium Difficile, Intestinal Microbiota and the Host Response in Hospitalised Patients.

MEDICAL RESEARCH COUNCIL

September 2012 - March 2018

Fighting Drug Failure (Marie Curie Fellowship)

EUROPEAN COMMISSION

October 2009 - September 2013

Phase IIa, randomised, open label, controlled trial of rostuvastatin for the prevention of aminoglycoside-induced kidney toxicity in children with cystic fibrosis (PROteKT)

THE MOULTON CHARITABLE FOUNDATION (UK)

June 2014 - January 2018

North of England Pharmacology Research Programme

THE CHESHIRE AND MERSEYSIDE COMPREHENSIVE LOCAL RESEARCH NETWORK (UK)

May 2011 - June 2015

Genetic mechanisms of HIV-related lipodystrophy.

MEDICAL RESEARCH COUNCIL

October 2002 - September 2005

Folate Augmentation of Treatment - Evaluation for Depression: a randomised controlled trial (FoIATED).

DEPARTMENT OF HEALTH & SOCIAL CARE (UK)

October 2006 - June 2011

The immunological response consequences of metabolic drug activation by dendritic cells.

WELLCOME TRUST (UK)

April 2006 - April 2009

Designing and analysing multi-arm multi-stage clinical trials with one or more endpoints

MEDICAL RESEARCH COUNCIL

September 2012 - June 2016

TAILoR (TelmisArtan and InsuLin Resistance in HIV): A dose-ranging Phase II randomised open trial of telmistartan as a strategy for the reduction of insulin resistance in HIV-positive individuals on Combination Antiretroviral Therapy (CART)

DEPARTMENT OF HEALTH & SOCIAL CARE (UK)

January 2012 - February 2020

Genetics of non-steroidal anti-inflammatory drugs (NSAIDs)-induced peptic ulceration: a genome wide association study.

ROYAL LIVERPOOL AND BROADGREEN UNIVERSITY HOSPITALS NHS TRUST (UK)

July 2010 - June 2011

Utilisation of the COTOX trial to study the biological mechanisms of co-trimoxazole hypersensitivity in HIV disease.

MEDICAL RESEARCH COUNCIL

January 1999 - January 2002

Mechanisms of toxicity of protease inhibitions.

AVERT (UK)

October 1998 - September 2001

Exploring oxidative stress pathways in epilepsy

REPUBLIC OF IRAQ MINISTRY OF EDUCATION🚩

October 2014 - September 2017

Randomisation within the database: a feasibility trial evaluating the comparative effects of statins in a research network of general practices RETRO-PRO

WELLCOME TRUST (UK)

January 2010 - December 2017

Non-Attrition HAART nanoparticle therapies for HIV/AIDS Drug Delivery

ENGINEERING & PHYSICAL SCIENCES RESEARCH COUNCIL

May 2009 - October 2012

Bench Fees for Azizan Binti Ab Ghani

MINISTRY OF HEALTH MALAYSIA (MALAYSIA)

September 2010 - August 2014

Hepatoxicity of antituberculosis drugs: An investigation of mechanisms.

MEDICAL RESEARCH COUNCIL

May 2001 - April 2004

Inflammatory bowel disease in children

CROHNS IN CHILDHOOD RESEARCH ASSOCIATION (UK)

December 2013 - February 2017

Prospective registry of inflammatory bowel diseases

ROYAL LIVERPOOL AND BROADGREEN UNIVERSITY HOSPITALS NHS TRUST (UK)

September 2010 - August 2011

Variability in response to warfarin: a prospective analysis of pharmacogenetic and environmental factors.

DEPARTMENT OF HEALTH & SOCIAL CARE (UK)

September 2004 - October 2009

The role of transporter proteins in the efficacy of imatinib and newer tyrosine kinase inhibitors in chronic myeloid leukaemia.

KAY KENDALL LEUKAEMIA FUND (UK)

June 2008 - June 2013

Adverse Drug Reactions in Children.

DEPARTMENT OF HEALTH & SOCIAL CARE (UK)

December 2007 - April 2013

Pharmacogenetics of Methadone response

NATIONAL HEALTH AND MEDICAL RESEARCH COUNCIL (AUSTRALIA)

September 2010 - February 2013

Department of Health Sponsored chair in pharmacogenetics.

DEPARTMENT OF HEALTH & SOCIAL CARE (UK)

September 2007 - March 2019

Investigation into the role of mycobacterial antigens in early mortality in patients treated for TB.

WELLCOME TRUST (UK)

November 2005 - December 2010

MerseyBeat - Best Evidence, Application and Translation of research

LIVERPOOL PRIMARY CARE TRUST (UK)

March 2008 - September 2019

A pharmacogenomic approach to coumarin anticoagulant therapy (PACT)

EUROPEAN COMMISSION

October 2008 - March 2013

Paediatric Pharmacology studies

ALDER HEY CHILDREN'S NHS FOUNDATION TRUST (UK)

July 2014 - June 2017

Applying innovative technologies to improve the benefit-risk ratio of drugs: developing a national resource underpinned by the infrastructure of the MRC Centre for Drug Safety Science

MEDICAL RESEARCH COUNCIL

April 2015 - March 2016

EURIPIDES - EUropean Research initiative to develop Imaging Probes for early In-vivo Diagnosis and Evaluation of response to therapeutic Substances

EUROPEAN COMMISSION

February 2008 - January 2013

The role of peripheral and liver-associated T lymphocytes in pathogenesis of alcholic liver disease.

ROYAL LIVERPOOL AND BROADGREEN UNIVERSITY HOSPITALS NHS TRUST (UK)

May 2004 - October 2005

Epidemiology of adverse drug reactions in hospitals.

MEDICINES CONTROL AGENCY

April 2001 - November 2003

The Role of Multidrug Transporters in causing Pharmacoresistance in Epilepsy

MEDICAL RESEARCH COUNCIL

January 2013 - August 2013

Investigation into the mechanisms of lamotrigine cutaneous toxicity.

MACMILLAN CANCER SUPPORT (UK)

February 1998 - March 2001

Genetic markers for carbamazepine-induced hypersensitivty syndrome

EPILEPSY RESEARCH INSTITUTE UK (UK)

June 2012 - November 2013

P-glycoprotein and efficacy of imatinib (Glivec).

ROYAL LIVERPOOL AND BROADGREEN UNIVERSITY HOSPITALS NHS TRUST (UK)

June 2002 - October 2003

Liverpool Health Partners - Drugs Theme Project Manager

LIVERPOOL HEALTH PARTNERS (UK)

April 2013 - September 2015

Effects of NRTIs on adipose function.

PENNINE ACUTE HOSPITALS NHS TRUST (UK)

January 2006 - June 2009

An investigation of the functional and regulatory role of GST-PI during chemical stress.

WELLCOME TRUST (UK)

September 2000 - April 2004

Effects within HAART on markers of adipose function.

PENNINE ACUTE HOSPITALS NHS TRUST (UK)

December 2005 - June 2009

Pharmacogenetics of antimicrobial drug-induced liver injury.

DEPARTMENT OF HEALTH & SOCIAL CARE (UK)

October 2004 - April 2008

Pharmacogenetics of GABAergic mechanisms of benefit and harm in epilepsy.

DEPARTMENT OF HEALTH & SOCIAL CARE (UK)

February 2005 - November 2010

North West Hub for Trial Methodology Research (NWHTMR)

MEDICAL RESEARCH COUNCIL

October 2008 - August 2014

Clerical assistant to work on EU-PACT study

DEPARTMENT OF HEALTH & SOCIAL CARE (UK)

July 2012 - March 2013

WEB-RADR

EUROPEAN COMMISSION

September 2014 - August 2017

Pharmacogenetics of NSAIDs

DELTA STATE UNIVERSITY (NIGERIA)

October 2011 - September 2014

Drugs used in the treatment of alcohol dependency – a UK wide drug utilisation study

MERSEY CARE NHS FOUNDATION TRUST (UK)

July 2012 - September 2015

Clostridium difficile infection – developing biomarkers of pathogenicity and disease relapse

ROYAL LIVERPOOL AND BROADGREEN UNIVERSITY HOSPITALS NHS TRUST (UK)

March 2010 - March 2011

A retrospective cohort study of children and young people taking warfarin at Alder Hey

CHILDRENS RESEARCH FUND (UK)

January 2010 - December 2010

Development and implementation of a model to improve alcohol services in primary and secondary care.

DEPARTMENT OF HEALTH & SOCIAL CARE (UK)

September 1998 - May 2001

Platelet polymorphism study.

BLACKPOOL VICTORIA HOSPITAL NHS TRUST (UK)

October 2006 - September 2007

Epilepsy Pharmacogenomics: delivering biomarkers for clinical use (EpiPGX)

EUROPEAN COMMISSION

October 2011 - September 2016

NIHR Senior Investigator Award

DEPARTMENT OF HEALTH & SOCIAL CARE (UK)

April 2008 - March 2020

Pharmacogenetics of statin-induced muscle toxicity: Exploration using the UK general practice research database (GRPD).

MEDICAL RESEARCH COUNCIL

March 2009 - February 2013

The Pharmacology of Nevirapine in Malawian Patients: Implications for Dosing and Understanding of Hypersensitivity Reactions.

WELLCOME TRUST (UK)

September 2006 - October 2009

Definition of chemical and immunological signals associated with the development of contact dermatitis.

BRITISH SKIN FOUNDATION (UK)

January 2006 - December 2008

Metformin and genetic polymorphisms of organic cation transporters.

ROYAL LIVERPOOL AND BROADGREEN UNIVERSITY HOSPITALS NHS TRUST (UK)

May 2005 - December 2008

Quantitative high-throughput proteomics for biomedical research.

MEDICAL RESEARCH COUNCIL

March 2005 - March 2008

Cost-effectiveness of pre-prescription pharmacogenetic testing for irinotecan.

NATIONAL ASSEMBLY FOR WALES (UK)

February 2007 - September 2008

Do transporter proteins contribute to clinical resistance to imatinib in chronic myeloid leukaemia? A combined study in Liverpool and Glasgow, correlating transporter expression and function with imatinib uptake and efflux.

LEUKAEMIA RESEARCH FUND

August 2004 - June 2008

SANAD and MESS-Linked DNA bank and relational database.

WELLCOME TRUST (UK)

June 2004 - May 2005

NIHR Portfolio Pharmacology studies

THE CHESHIRE AND MERSEYSIDE COMPREHENSIVE LOCAL RESEARCH NETWORK (UK)

February 2012 - March 2014

SAFE-T

EUROPEAN COMMISSION

January 2011 - June 2015

Cell culture laboratory.

WELLCOME TRUST (UK)

June 2000 - April 2001

Investigation of the role of ABCB5 in corticosteroid transport and response in IBD

NAT ASSOC FOR COLITIS & CROHNS DISEASE (UK)

November 2009 - February 2012

PREDICTION-ADR: Personalisation of tREatment In Cardiovascular disease through next generation sequencing in Adverse Drug Reactions

EUROPEAN COMMISSION

September 2013 - February 2017

Antiepileptic drug transport at the blood-brain barrier; more than just P-glycoprotein

EPILEPSY RESEARCH INSTITUTE UK (UK)

October 2010 - September 2014

Individual susceptibility to Clostridium Difficile Toxin Disease.

ROYAL LIVERPOOL AND BROADGREEN UNIVERSITY HOSPITALS NHS TRUST (UK)

January 2000 - August 2004

PAMPERS - Paediatric Accelerator Mass Spectrometry Evaluation Research Study

INSTYTUT FARMACEUTYCZNY (POLAND), MEDICAL RESEARCH COUNCIL

September 2011 - December 2014

High Throughput Sequencing Hub for the North of England

MEDICAL RESEARCH COUNCIL

September 2009 - December 2012

BRC safety of antimicrobials theme.

DEPARTMENT OF HEALTH & SOCIAL CARE (UK)

September 2007 - March 2012

Andrew Swale - NIHR fellowship

ROYAL LIVERPOOL AND BROADGREEN UNIVERSITY HOSPITALS NHS TRUST (UK)

April 2012 - September 2013

Support for the Pharmacology Research Portfolio

ROYAL LIVERPOOL AND BROADGREEN UNIVERSITY HOSPITALS NHS TRUST (UK)

August 2014 - March 2018

Research Collaborations